The interim report from Resistentia’s phase I trial with RP01, a novel universal allergy immunotherapy, shows positive results. The therapy was well tolerated and the healthy volunteers developed anti-IgE antibodies, supporting the novel mode of action of the immunotherapy.

”There is a tremendous need for an efficient, long-acting and cost-effective asthma and allergy treatment. The strength of the interim report has encouraged us to step up our development efforts ahead of the upcoming phase II trials,” says Marcus Bosson, CEO of Resistentia Pharmaceuticals. He adds: ”We can see that this immunotherapy produces the desired effect. This is an important milestone in the development process”.

RP01 induces the immune system to produce antibodies against Immunoglobulin E (IgE), the key molecule triggering allergic reactions. The antibodies induced by the immunotherapy bind to IgE and block it from starting allergic reactions. The treatment thus has the potential to block allergenic...